Your browser doesn't support javascript.
loading
Advances in follicle stimulating hormone receptor and its targeted drugs / 肿瘤
Tumor ; (12): 863-867, 2014.
Article in Chinese | WPRIM | ID: wpr-848872
ABSTRACT
Follicle stimulating hormone receptor (FSHR) belongs to the G protein-coupled receptor family and is only low-expressed in reproductive organs of mammals. Recent studies have shown that FSHR is overexpressed in vascular endothelium of multiple types of human tumors including prostate cancer, breast cancer, liver cancer and kidney cancer, etc, and it plays an important role in the progression of cancer. Thus, FSHR is a potential target for diagnosis and treatment of tumors. Development of drugs targeting FSHR is beneficial to diagnosis, targeted therapy, selection of individualized drug therapy and prognosis of tumors. This paper summarizes the advances in FSHR and its specific ligands.

Full text: Available Index: WPRIM (Western Pacific) Language: Chinese Journal: Tumor Year: 2014 Type: Article

Similar

MEDLINE

...
LILACS

LIS

Full text: Available Index: WPRIM (Western Pacific) Language: Chinese Journal: Tumor Year: 2014 Type: Article